Clinical trials: Dual Antiplatelet Therapy
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and…
- Trial name
- NCT05491200
- Testing
- Prasugrel based short DAPT, Prasugrel based standard DAPT, OCT guided revascularization
- Where
- 27 sites in Belgium, Czechia and 4 more
- Volunteers
- 1,656 people
- Sponsor
- Research Maatschap Cardiologen Rotterdam Zuid
High Ischemic Risk
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous…
- Trial name
- NCT04989257
- Testing
- Ticagrelor-based dual-antiplatelet therapy, Clopidogrel-based dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,488 people
- Sponsor
- Yonsei University
Coronary Heart Disease (CHD)
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in…
- Trial name
- KONG-FREEDOM-I (NCT07587099)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- 14 sites in China
- Volunteers
- 2,170 people
- Sponsor
- Gan Lijun
Coronary Artery Disease, Coronary Artery Bypass Grafting
TOP-CABG Trial: Follow-up Extension (TOP-CABG FE)
To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding
- Trial name
- NCT07871591
- Volunteers
- 2,290 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Coronary Syndrome, Coronary Artery Disease
IPD Meta-analysis of De-escalation Treatment Strategy After PCI in ACS
We will perform a systemic review of previously published data and an updated patient-level meta-analysis of studies, including the most recent publications.
- Trial name
- NCT04848766
- Testing
- De-escalation Treatment Strategy of dual antiplatelet therapy
- Where
- South Korea
- Volunteers
- 9,000 people
- Sponsor
- Seoul National University Hospital
Percutaneous Coronary Intervention
Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis
Patients undergoing the percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) are enrolled. All patients will be randomized to receive either 12 months or 24 months of dual antiplatelet therapy with a P2Y12…
- Trial name
- NCT02402491
- Testing
- 12 months of P2Y12 receptor antagonist, 24 months of P2Y12 receptor antagonist, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Stable Chronic Angina
Ticagrelor vs. Clopidogrel in Post PCI Patients
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg…
- Trial name
- NCT05858918
- Testing
- Clopidogrel, Ticagrelor
- Where
- Iran
- Volunteers
- 476 people
- Sponsor
- Shiraz University of Medical Sciences
Acute Stroke, Transient Ischemic Attack
Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis
Large-artery stenosis plays an important role in the occurrence of ischemic stroke. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy…
- Trial name
- INSPIRES (NCT03635749)
- Testing
- Intensive antiplatelet, Standard antiplatelet, Immediate high-intensity statin
- Where
- 113 sites in China
- Volunteers
- 6,100 people
- Sponsor
- Beijing Tiantan Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
- Trial name
- PREMIUM (NCT05709626)
- Testing
- No aspirin (Prasugurel monotherapy), 12-month DAPT
- Where
- Japan
- Volunteers
- 2,258 people
- Sponsor
- Kindai University
Coronary Artery Disease, Acute Coronary Syndrome
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
Our first hypothesis is that dose adjustment of aspirin and clopidogrel based on biological monitoring reduces the rate of severe cardiovascular complications compared to a conventional strategy in patients scheduled for drug…
- Trial name
- ARCTIC (NCT00827411)
- Testing
- Aspirin and clopidogrel / Prasugrel, VerifyNow, Aspirin
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
- Conditions
- Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged, Percutaneous Coronary Intervention
- Trial name
- NCT04999293
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Aortic Valve Stenosis, Stroke
Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI
The purpose of this study is to determine the incidence of major vascular events (ischemic or haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral anticoagulation or dual antiplatelet therapy)…
- Trial name
- AUREA (NCT01642134)
- Testing
- aspirin+clopidogrel (Duoplavin)
- Where
- 4 sites in Spain
- Volunteers
- 124 people
- Sponsor
- Andres Iñiguez Romo, MD, PhD
Angina Pectoris, Silent Ischemia
Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy
Prospective, randomized, non-inferiority, multicenter, international study.In total 4000 patients (70 centers in Europe) with de novo lesions in native coronary arteries who meet the eligibility criteria randomized to 6 versus 12…
- Trial name
- NCT00944333
- Testing
- Clopidogrel
- Where
- Italy
- Volunteers
- 1,378 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Chronic Coronary Syndrome
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor…
- Trial name
- STELAR (NCT07080684)
- Testing
- Ticagrelor 60 mg, clopidogrel 75 mg
- Volunteers
- 1,000 people
- Sponsor
- University of Messina
Aneurysm, Cerebral, Endovascular Procedures
Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
Perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using P2Y12 assay in patients with high on-treatment platelet reactivity…
- Trial name
- NCT03581409
- Testing
- Aspirin, Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Coronary Artery Disease, Aspirin Resistance
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
Reactive platelet hyperactivity following coronary artery bypass grafting (CABG) might lead to thrombotic complications and major ischemic cardiac events.
- Trial name
- NCT01159639
- Testing
- Clopidogrel
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- University of Zagreb